JP5876826B2 - 糖尿病前症及び2型糖尿病におけるアポリポタンパク質ciii - Google Patents
糖尿病前症及び2型糖尿病におけるアポリポタンパク質ciii Download PDFInfo
- Publication number
- JP5876826B2 JP5876826B2 JP2012519652A JP2012519652A JP5876826B2 JP 5876826 B2 JP5876826 B2 JP 5876826B2 JP 2012519652 A JP2012519652 A JP 2012519652A JP 2012519652 A JP2012519652 A JP 2012519652A JP 5876826 B2 JP5876826 B2 JP 5876826B2
- Authority
- JP
- Japan
- Prior art keywords
- apociii
- diabetes
- type
- biological sample
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000009104 prediabetes syndrome Diseases 0.000 title claims description 55
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims description 49
- 206010018429 Glucose tolerance impaired Diseases 0.000 title claims description 28
- 208000001280 Prediabetic State Diseases 0.000 title claims description 27
- 108010056301 Apolipoprotein C-III Proteins 0.000 title description 89
- 102000030169 Apolipoprotein C-III Human genes 0.000 title description 89
- 206010022489 Insulin Resistance Diseases 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 239000012472 biological sample Substances 0.000 claims description 14
- 238000004949 mass spectrometry Methods 0.000 claims description 12
- 201000004569 Blindness Diseases 0.000 claims description 4
- 206010040943 Skin Ulcer Diseases 0.000 claims description 4
- 238000002266 amputation Methods 0.000 claims description 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
- 201000006370 kidney failure Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000002705 Glucose Intolerance Diseases 0.000 description 28
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 23
- 239000008103 glucose Substances 0.000 description 23
- 210000002381 plasma Anatomy 0.000 description 22
- 239000000090 biomarker Substances 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 239000000523 sample Substances 0.000 description 14
- 230000001747 exhibiting effect Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000007410 oral glucose tolerance test Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000002641 glycemic effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 150000004676 glycans Chemical group 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 125000005629 sialic acid group Chemical group 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101000793223 Homo sapiens Apolipoprotein C-III Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 238000004816 paper chromatography Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000019267 Hepatic lipases Human genes 0.000 description 1
- 108050006747 Hepatic lipases Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102000043296 Lipoprotein lipases Human genes 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 238000011157 data evaluation Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001019 normoglycemic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 1
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Description
善する治療を開発するための更なる代謝性又は内分泌性標的に対する必要性も存在する。
本明細書で使用されている技術用語及び科学用語は全て、別様に定義されていない限り、本発明が関する分野の当業者が一般的に理解する意味を有する。本明細書で使用される場合、以下の用語は、別様に指定されていない限り、それらに帰すべき意味を有する。
る基準範囲は、110〜125mg/dLの空腹時血糖値、及び/又は140〜199mg/dLの2時間経口グルコース負荷試験値である。
実施例
ヒト血漿に由来するアポリポタンパク質CIII及びその変異体の分析
本発明の1つの例示的実施形態は、臨床的に規定された試料の集団を区別するバイオマーカー(複数可)として使用するためのApoCIII及びその変異体の濃度測定である。この例示的実施形態の分析を、質量分析イムノアッセイ(MSIA)技術を使用して実施した。
)が、異なる試料間で調節されていることを明白に示す。図1には、ApoCIII及びその変異体の存在量が、正常耐糖能(NGT)を示す患者、耐糖能異常(IGT、糖尿病前症)の患者、及び2型糖尿病(DM)の患者に由来するヒト血漿試料で異なることが例示されている。図1には、IGT及びDMと診断された患者由来の試料において、ApoCIII変異体は全て増加したことが示されている。
度及び特異性は、上記の表1に示されている。
Claims (4)
- 対象体の糖尿病前症を診断するための指標として、前記対象体の生体試料中のApoCIII(1)のレベルを検出する方法であって、前記ApoCIII(1)のレベルが1.66を超えるカットオフ値を有するかどうかを決定することを含み、前記カットオフ値は前記生体試料から単離されたApoCIII(1)を質量分析することにより決定される、方法。
- 対象体の2型糖尿病を診断するための指標として、前記対象体の生体試料中のApoCIII(1)のレベルを検出する方法であって、前記ApoCIII(1)のレベルが1.914を超えるカットオフ値を有するかどうかを決定することを含み、前記カットオフ値は前記生体試料から単離されたApoCIII(1)を質量分析することにより決定される、方法。
- 1つ又は複数の対象体の2型糖尿病、糖尿病前症、インスリン抵抗性、及びそれらの関連状態のうちの少なくとも1つを判定、診断、またはモニターするために、総ApoCIIIを分析する方法であって、前記対象体の生体試料から単離された総ApoCIIIを質量分析して前記総ApoCIIIのレベルが2.609を超えるカットオフ値を有するかどうかを決定することを含み、前記関連状態は、心臓発作、皮膚潰瘍形成、失明、切断、及び腎不全からなる群より選択される、方法。
- 1つ又は複数の対象体の2型糖尿病、糖尿病前症、インスリン抵抗性、及びそれらの関連状態のうちの少なくとも1つを判定、診断、またはモニターするために、ApoCIII(1)を分析する方法であって、前記対象体の生体試料から単離されたApoCIII(1)を質量分析して前記ApoCIII(1)のレベルが1.66を超えるカットオフ値を有するかどうかを決定することを含み、前記関連状態は、心臓発作、皮膚潰瘍形成、失明、切断、及び腎不全からなる群より選択される、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22350209P | 2009-07-07 | 2009-07-07 | |
US61/223,502 | 2009-07-07 | ||
PCT/US2010/040998 WO2011005718A1 (en) | 2009-07-07 | 2010-07-03 | Apolipoprotein ciii in pre- and type 2 diabetes |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012533066A JP2012533066A (ja) | 2012-12-20 |
JP2012533066A5 JP2012533066A5 (ja) | 2013-05-30 |
JP5876826B2 true JP5876826B2 (ja) | 2016-03-02 |
Family
ID=43427312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012519652A Active JP5876826B2 (ja) | 2009-07-07 | 2010-07-03 | 糖尿病前症及び2型糖尿病におけるアポリポタンパク質ciii |
Country Status (5)
Country | Link |
---|---|
US (2) | US20110008901A1 (ja) |
EP (1) | EP2451466B1 (ja) |
JP (1) | JP5876826B2 (ja) |
CN (1) | CN102481319A (ja) |
WO (1) | WO2011005718A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8557513B2 (en) * | 2011-06-27 | 2013-10-15 | Biocrine Ab | Methods for treating and/or limiting development of diabetes |
US9125255B2 (en) | 2012-05-03 | 2015-09-01 | Abl Ip Holding Llc | Networked architecture for system of lighting devices having sensors, for intelligent applications |
US9901562B2 (en) | 2013-04-04 | 2018-02-27 | Lycored Ltd. | Anti-inflammatory omega-3 synergistic combinations |
AU2018361957B2 (en) * | 2017-10-31 | 2023-05-25 | Staten Biotechnology B.V. | Anti-ApoC3 antibodies and methods of use thereof |
CN114354827A (zh) * | 2022-03-21 | 2022-04-15 | 天津云检医疗器械有限公司 | 代谢标志物及其在制备2型糖尿病的风险预测试剂盒中的应用和试剂盒 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020164818A1 (en) * | 1995-05-23 | 2002-11-07 | Gruber Karl F. | Mass spectrometric immunoassay analysis of specific proteins and variants present in various biological fluids |
WO2002082051A2 (en) * | 2001-01-17 | 2002-10-17 | Tubbs Kemmons A | An integrated high throughput system for the analysis of biomolecules |
JP2005503537A (ja) * | 2001-01-17 | 2005-02-03 | エー. タブス,ケモンズ | 生体分子分析用ハイ・スループット統合システム |
US6677303B2 (en) * | 2001-04-30 | 2004-01-13 | Syn X Pharma | Biopolymer marker indicative of disease state having a molecular weight of 1097 daltons |
PL1623228T3 (pl) * | 2003-04-29 | 2013-04-30 | Biocrine Ab | APOCIII i leczenie oraz diagnozowanie cukrzycy |
US20070087448A1 (en) * | 2004-02-16 | 2007-04-19 | Nelsestuen Gary L | Biological profiles and methods of use |
US8343534B2 (en) * | 2004-04-23 | 2013-01-01 | The Procter & Gamble Company | Tissue including a volatile rhinological composition |
US20060110082A1 (en) * | 2004-11-24 | 2006-05-25 | Sauer-Danfoss Inc. | Compact unitized cradle swashplate bearing |
JPWO2006073195A1 (ja) * | 2005-01-07 | 2008-06-12 | 敏一 吉川 | 糖尿病の予知・診断方法および糖尿病予知・診断用キット |
CN101166981A (zh) * | 2005-04-11 | 2008-04-23 | 阿斯利康(瑞典)有限公司 | 一种用于诊断 2型糖尿病、代谢综合征、亚临床动脉粥样硬化、心肌梗死、中风或糖尿病的临床表现的方法和试剂盒 |
WO2007025174A2 (en) * | 2005-08-26 | 2007-03-01 | Vascular And Endovascular Surgical Technologies, Inc. | Endograft |
US20070112055A1 (en) * | 2005-09-30 | 2007-05-17 | Glenmark Pharmaceuticals Limited | Crystalline forms of almotriptan and processes for their preparation |
JP5688829B2 (ja) * | 2005-11-11 | 2015-03-25 | 敏一 吉川 | 示差的な糖尿病の予知・診断方法および糖尿病予知・診断用キット |
MX2008012135A (es) * | 2006-03-23 | 2009-03-12 | Emelita De Guzman Breyer | Tecnica de identificacion genetica de apolipoproteina. |
WO2007132291A2 (en) * | 2006-05-15 | 2007-11-22 | Digilab, Inc. | Biomarkers for pre-form of type 2 diabetes and methods for detecting the presence of absence of a pre-form of type 2 diabetes |
US20080300170A1 (en) * | 2006-09-01 | 2008-12-04 | Cohava Gelber | Compositions and methods for diagnosis and treatment for type 2 diabetes |
-
2010
- 2010-07-02 US US12/829,891 patent/US20110008901A1/en not_active Abandoned
- 2010-07-03 JP JP2012519652A patent/JP5876826B2/ja active Active
- 2010-07-03 WO PCT/US2010/040998 patent/WO2011005718A1/en active Application Filing
- 2010-07-03 CN CN2010800370600A patent/CN102481319A/zh active Pending
- 2010-07-03 EP EP10797691.2A patent/EP2451466B1/en active Active
-
2015
- 2015-01-30 US US14/610,813 patent/US20150212100A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2012533066A (ja) | 2012-12-20 |
EP2451466B1 (en) | 2016-03-30 |
US20150212100A1 (en) | 2015-07-30 |
CN102481319A (zh) | 2012-05-30 |
EP2451466A4 (en) | 2012-12-12 |
US20110008901A1 (en) | 2011-01-13 |
EP2451466A1 (en) | 2012-05-16 |
WO2011005718A1 (en) | 2011-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080176333A1 (en) | Analysis of Proteins from Biological Fluids Using Mass Spectrometric Immunoassay | |
Cho et al. | Biomarker Characterization by MALDI–TOF/MS | |
JP2011515680A (ja) | 糖尿病のためのバイオマーカーおよびアッセイ | |
Riaz et al. | Proteomic identification of human urinary biomarkers in diabetes mellitus type 2 | |
JP5876826B2 (ja) | 糖尿病前症及び2型糖尿病におけるアポリポタンパク質ciii | |
US20150090010A1 (en) | Method for diagnosing heart failure | |
WO2007008158A1 (en) | Method for diagnosing multiple sclerosis | |
CN112599239B (zh) | 代谢物标志物及其在脑梗死诊断中的应用 | |
WO2021232211A1 (zh) | 诊断肾病的标志物以及诊断方法 | |
CN112305122B (zh) | 代谢物标志物及其在疾病中的应用 | |
JP5748751B2 (ja) | 糖尿病前症及び2型糖尿病における血清アミロイドの表現型比率 | |
WO2024007778A1 (zh) | 一种血浆分子标志物犬尿氨酸在早期心力衰竭检测中的应用 | |
Joshi et al. | Recent progress in mass spectrometry-based urinary proteomics | |
KR102377089B1 (ko) | 전당뇨 진단 키트 및 진단 방법 | |
CN112630344B (zh) | 代谢标志物在脑梗死中的用途 | |
WO2024109768A1 (zh) | 基于血液代谢物的阿尔茨海默症标志物及其应用 | |
CN112599237B (zh) | 一种生物标志物及其在脑梗死诊断中的应用 | |
CN112305089B (zh) | 一种慢性肾病诊断生物标记物及其应用 | |
WO2024108604A1 (zh) | 基于血液代谢物的神经退行性疾病标志物及其应用 | |
JPH04505218A (ja) | 糖尿病性異常を予言する物質の定量分析法 | |
WO2024109767A1 (zh) | 基于粪便代谢物的阿尔兹海默症标志物及其应用 | |
WO2023079706A1 (ja) | 糖尿病性腎症の判定方法 | |
WO2024120401A1 (zh) | 急性主动脉夹层血浆生物标志物及其应用 | |
CN113655141A (zh) | 一种早期预警重症急性胰腺炎的血清极性小分子预测模型与应用 | |
CN117452003A (zh) | 血清多肽标志物prpf19在制备黑素瘤血清诊断产品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130318 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130906 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130917 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131211 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140117 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140124 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140207 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140317 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140930 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150602 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150826 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160112 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160122 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5876826 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |